The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2014
A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia. Randomized,Open Label,Control
Epistemonikos ID: 27ac599d6fe95d9a2fc779a3fd834ada16254336
First added on: Jan 21, 2022